Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2015-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/apt.13181PMID 25858208
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.

  2016cited by this paper
• Therapy‐related peripheral neuropathy in multiple myeloma patients

  2015cited by this paper
• Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.

  2015cited by this paper
• Inflammatory bowel disease: clinical aspects and treatments

  2014cited by this paper
• Use of placebo in a trial of thalidomide for pediatric Crohn disease.

  2014cited by this paper
• The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses

  2014cited by this paper
• Inflammatory Bowel Disease in Children of Manitoba: 30 Years’ Experience of a Tertiary Center

  2014cited by this paper
• Cytokines in inflammatory bowel disease

  2014influential reference
• TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis.

  2013cited by this paper
• INCIDENCE AND PREVALENCE OF INFLAMMATORY BOWEL DISEASE

  2013cited by this paper
• Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial.

  2013influential reference
• The burden of inflammatory bowel disease in Europe.

  2013cited by this paper
• Thalidomide in Gastrointestinal Disorders

  2012cited by this paper
• Thalidomide Use and Outcomes in Pediatric Patients With Crohn Disease Refractory to Infliximab and Adalimumab

  2012cited by this paper
• Recent Trends in the Prevalence of Crohn’s Disease and Ulcerative Colitis in a Commercially Insured US Population

  2012cited by this paper
• Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.

  2012cited by this paper
• Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration

  2011cited by this paper
• Epidemiology of pediatric inflammatory bowel disease: A systematic review of international trends

  2011cited by this paper
• Treatment of pediatric refractory Crohn's disease with thalidomide.

  2011cited by this paper
• Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases.

  2011cited by this paper
• Caspase-8 regulates TNF-alpha induced epithelial necroptosis and terminal ileitis

  2011cited by this paper
• Review article: remission rates achievable by current therapies for inflammatory bowel disease

  2011cited by this paper
• Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

  2011cited by this paper
• Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.

  2011cited by this paper
• Inflammatory bowel disease.

  2011cited by this paper
• State-of-the-Art Medical Therapy of the Adult Patient with IBD: The Immunomodulators

  2011cited by this paper
• Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

  2011cited by this paper
• Inflammatory bowel disease.

  2011cited by this paper
• Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways

  2010cited by this paper
• Interferon-gamma regulates intestinal epithelial homeostasis through converging beta-catenin signaling pathways.

  2010cited by this paper
• Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC).

  2010cited by this paper
• Thalidomide and thalidomide analogues for induction of remission in Crohn's disease.

  2009cited by this paper
• Prospective Evaluation of Anti-Tumor Necrosis Factor Therapy Guided by Magnetic Resonance Imaging for Crohn's Perineal Fistulas

  2009cited by this paper
• Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease.

  2009cited by this paper
• Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.

  2009influential reference
• Assessing Risk of Bias in Included Studies

  2008cited by this paper
• Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.

  2008cited by this paper
• Chapter 8: Assessing risk of bias in included studies

  2008cited by this paper
• Traditional corticosteroids for induction of remission in Crohn's disease.

  2008cited by this paper
• Anti-tumor necrosis factor therapy for pediatric inflammatory bowel diseases.

  2008cited by this paper
• Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies

  2007cited by this paper
• A randomized, double‐blind, placebo‐controlled trial of lenalidomide in the treatment of moderately severe active Crohn’s disease

  2007influential reference
• Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

  2007cited by this paper
• Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases

  2007cited by this paper
• Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long‐term results

  2007influential reference
• Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.

  2007influential reference
• IFN-gamma-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction.

  2006cited by this paper
• Role of angiogenesis in inflammatory bowel disease

  2006cited by this paper
• Thalidomide: current status.

  2006cited by this paper
• Activation of Nuclear Factor-κB via Endogenous Tumor Necrosis Factor α Regulates Survival of Axotomized Adult Sensory Neurons

  2005cited by this paper
• Activation of nuclear factor-kappaB via endogenous tumor necrosis factor alpha regulates survival of axotomized adult sensory neurons.

  2005cited by this paper
• Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease

  2004cited by this paper
• A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease.

  2004cited by this paper
• Management of thalidomide toxicity.

  2003cited by this paper
• Corticosteroids for maintenance of remission in Crohn's disease.

  2003cited by this paper
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

  2002cited by this paper
• An open‐label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease

  2002cited by this paper
• Mucosal and Invading Bacteria in Patients with Inflammatory Bowel Disease Compared with Controls

  2002cited by this paper
• Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's disease

  2002influential reference
• Management of Crohn's disease in adults

  2001cited by this paper
• Thalidomide impairment of trinitrobenzene sulphonic acid‐induced colitis in the rat–role of endothelial cell‐leukocyte interaction

  2001cited by this paper
• Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity.

  2001cited by this paper
• Efficacy of Long-Term Treatment With Thalidomide in Children and Young Adults With Crohn Disease: Preliminary Results

  2001cited by this paper
• Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature

  2001cited by this paper
• Management of Crohn's Disease in Adults

  2001cited by this paper
• Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity*

  2001cited by this paper
• Manipulation of cytokines in the management of patients with inflammatory bowel disease

  2000cited by this paper
• An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

  1999cited by this paper
• On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease

  1999cited by this paper
• Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

  1999cited by this paper
• Infliximab for the treatment of fistulas in patients with Crohn'S disease.

  1999cited by this paper
• Infliximab for the treatment of fistulas in patients with Crohn's disease.

  1999cited by this paper
• Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease.

  1997cited by this paper
• A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease.

  1997cited by this paper
• A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

  1997cited by this paper
• Inhibition of IL-12 production by thalidomide.

  1997cited by this paper
• A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

  1997cited by this paper
• Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses.

  1996influential reference
• Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5.

  1996cited by this paper
• Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

  1995cited by this paper
• Angiogenesis in cancer, vascular, rheumatoid and other disease

  1995influential reference
• The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen‐ and antigen‐stimulated human peripheral blood mononuclear cell cultures

  1995influential reference
• Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease

  1994cited by this paper
• Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease.

  1994cited by this paper
• Thalidomide is an inhibitor of angiogenesis.

  1994cited by this paper
• Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells.

  1994cited by this paper
• Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.

  1993cited by this paper
• Enhand secretion of tumour necrosis factor‐alpha, IL‐6, and IL‐1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease

  1993cited by this paper
• Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

  1993cited by this paper
• Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa.

  1993cited by this paper
• Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

  1991cited by this paper
• Tumour necrosis factor‐alpha and interferon‐gamma production measured at the single cell level in normal and inflamed human intestine

  1990cited by this paper
• TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

  1989cited by this paper
• Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo.

  1987cited by this paper
• Inflammatory bowel disease

  year unknowncited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Off-label use of thalidomide in children with Crohn's disease and inflammatory bowel diseases

  2025influential citation
• Renaissance of Phoenix Drug Thalidomide—New Insights into Practical Clinical Application and Optimization Strategies for Managing Adverse Effects in Digestive Diseases

  2025cites this paper
• Rifaximin Inhibits Small Bowel Angiodysplasia-Associated Angiogenesis by Attenuating LncRNA-HIF1A-AS2/miR-153-3p/HIF-1 α/Ang-2 Axis

  2025cites this paper
• A review of thalidomide and digestive system related diseases

  2025cites this paper
• Pharmacogenetics in personalized treatment in pediatric patients with inflammatory bowel disease (IBD)

  2024cites this paper
• Refractory Crohn’s Disease: Perspectives, Unmet Needs and Innovations

  2024cites this paper
• Optimization of a gelatin/carboxymethylcellulose-based probiotic microcapsule and its application in preventing dextran sodium sulfate-induced colitis in mice.

  2024cites this paper
• Efficacy and safety of thalidomide in gastrointestinal angiodysplasias: systematic review and meta-analysis with trial sequential analysis of randomized controlled trials

  2024cites this paper
• Consenso colombiano de la enfermedad inflamatoria intestinal pediátrica

  2023cites this paper
• Exploring the Targets and Molecular Mechanisms of Thalidomide in the Treatment of Ulcerative Colitis: Network Pharmacology and Experimental Validation.

  2023cites this paper
• Analysis of CD4+ T-helper-associated hub gene signature and immune dysregulation via RNA-sequencing data in a mouse tail model of lymphedema

  2023cites this paper
• Efficacy and Tolerance of Thalidomide in Patients With Very Early Onset Inflammatory Bowel Disease

  2023cites this paper
• Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia

  2022influential citation
• Polydopamine-coated Thalidomide Nanocrystals Promote DSS-induced Murine Colitis Recovery Through Macrophage M2 Polarization Together with the Synergistic Anti-inflammatory and Anti-angiogenic Effects.

  2022cites this paper
• Thalidomide combined with endoscopy in the treatment of Cronkhite-Canada syndrome: A case report

  2022cites this paper
• Application of Reverse Docking in the Research of Small Molecule Drugs and Traditional Chinese Medicine.

  2021cites this paper
• Metalloproteinases in Inflammatory Bowel Diseases

  2021cites this paper
• Thalidomide Attenuates Colitis and Is Associated with the Suppression of M1 Macrophage Polarization by Targeting the Transcription Factor IRF5

  2021cites this paper
• Development of Anti-fibrotic Therapy in Stricturing Crohn's Disease: Lessons from Randomized Trials in Other Fibrotic Diseases.

  2021cites this paper
• Thalidomide may be an effective medicine for Blau Syndrome

  2021cites this paper
• Efficacy and Safety of Thalidomide in Crohn’s Disease Patients with Perianal Fistula and Abscess

  2021cites this paper
• Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia.

  2020cites this paper
• Prevention of COVID-19 in patients with IBD

  2020cites this paper
• Thalidomide as a treatment for inflammatory bowel disease in children and adolescents: A systematic review

  2020cites this paper
• The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update.

  2020cites this paper
• Thalidomide Combined With Azathioprine as Induction and Maintenance Therapy for Azathioprine-Refractory Crohn's Disease Patients

  2020cites this paper
• Perianal Crohn’s Disease

  2019cites this paper
• Early onset first-episode psychosis during treatment with thalidomide for refractory ulcerative colitis: a case report

  2019cites this paper
• A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease

  2019influential citation
• Biomarkers in Inflammatory Bowel Diseases

  2019influential citation
• Consider using biological agents or stem cell therapy when managing perianal Crohn’s disease

  2018cites this paper
• Peripheral neuropathy and gastroenterologic disorders: an overview on an underrecognized association

  2018cites this paper
• Fibrostenotic Inflammatory Bowel Disease

  2018cites this paper
• Consider using biological agents or stem cell therapy when managing perianal Crohn’s disease

  2018cites this paper
• Anti-Fibrotic Therapies from Other Organs: What the Gut Can Learn from the Liver, Skin, Lung and Heart

  2018cites this paper
• Risk Factors and Outcomes of Thalidomide-induced Peripheral Neuropathy in a Pediatric Inflammatory Bowel Disease Cohort

  2017cites this paper
• Treating children with inflammatory bowel disease: Current and new perspectives

  2017cites this paper
• A Novel Green Synthesis of Thalidomide and Analogs

  2017cites this paper
• Thalidomide in Refractory Crohn's Disease: Risk-Benefit Ratio.

  2017cites this paper
• Thalidomide is a therapeutic agent that is effective in inducing and maintaining endoscopic remission in adult CD patients.

  2017cites this paper
• Pharmacological Approach to the Management of Crohn’s Disease Patients with Perianal Disease

  2017cites this paper
• Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease

  2017cites this paper
• A Brighter Side to Thalidomide: Its Potential Use in Immunological Disorders.

  2017cites this paper
• Thalidomide for inflammatory bowel disease

  2016cites this paper
• Thalidomide Embryopathy - Orthopaedic aspects. Degenerative changes and quality of life at age 45

  2016cites this paper
• Health-related quality of life and function in middle-aged individuals with thalidomide embryopathy

  2016cites this paper
• Management of complex perianal Crohn’s disease

  2016influential citation
• Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic recurrence

  2016cites this paper
• Peripheral neuropathy: an underreported neurologic manifestation of inflammatory bowel disease.

  2015cites this paper
• World Journal of Gastroenterology

  year unknowncites this paper